3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
102
Carcinoma, Intraductal, Noninfiltrating
12
Breast Carcinoma In Situ
10
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Breast Neoplasms, Male
6
Neoplasms
5
Glioblastoma
5
Central Nervous System Neoplasms
5
Prostatic Neoplasms
4
Gliosarcoma
4
Inflammatory Breast Neoplasms
3
Glioma
3
Brain Neoplasms
3
Astrocytoma
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Glioma, Subependymal
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Breast Cancer Female
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Risk Reduction Behavior
1
Interventions
Tamoxifen
2
Paclitaxel
2
pyrotinib
1
pembrolizumab
1
palbociclib
1
iniparib
1
darolutamide
1
Thioctic Acid
1
Pentoxifylline
1
Metformin
1
Letrozole
1
Doxorubicin
1
Cyclophosphamide
1
Capecitabine
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Female
×
Tamoxifen
×
Clear all
NCT03917082
2023-06-15
LALEAST
British Columbia Cancer Agency
Phase 2
Active not recruiting
290 enrolled
NCT03879174
2019-03-18
Pembro
Mediclinic Middle East
Phase 2
Unknown
25 enrolled